ValuEngine downgraded shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) from a sell rating to a strong sell rating in a research report released on Friday.

PETX has been the topic of a number of other reports. Jefferies Group LLC set a $8.00 price objective on Aratana Therapeutics and gave the company a buy rating in a research report on Thursday, June 8th. Zacks Investment Research upgraded Aratana Therapeutics from a hold rating to a buy rating and set a $8.00 price objective on the stock in a research report on Tuesday, July 4th. BidaskClub cut Aratana Therapeutics from a hold rating to a sell rating in a research report on Tuesday, August 1st. Stifel Nicolaus lowered their price objective on Aratana Therapeutics from $8.00 to $7.00 and set a buy rating on the stock in a research report on Wednesday, May 10th. Finally, Lake Street Capital lowered their price objective on Aratana Therapeutics from $15.00 to $10.00 and set a buy rating on the stock in a research report on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $8.25.

Aratana Therapeutics (PETX) opened at 5.72 on Friday. The firm has a 50-day moving average of $6.24 and a 200-day moving average of $6.22. The firm’s market cap is $245.97 million. Aratana Therapeutics has a 12-month low of $4.97 and a 12-month high of $10.73.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. The business had revenue of $5.16 million for the quarter, compared to analysts’ expectations of $4.50 million. Aratana Therapeutics had a negative return on equity of 51.21% and a negative net margin of 642.93%. Aratana Therapeutics’s quarterly revenue was down 86.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.61 earnings per share. On average, analysts expect that Aratana Therapeutics will post ($1.09) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Aratana Therapeutics, Inc. (PETX) Downgraded by ValuEngine” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/04/aratana-therapeutics-inc-petx-downgraded-by-valuengine.html.

A number of large investors have recently made changes to their positions in PETX. Financial Counselors Inc. bought a new stake in Aratana Therapeutics in the first quarter valued at $101,000. American International Group Inc. grew its position in Aratana Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,354 shares during the period. Janney Montgomery Scott LLC grew its position in Aratana Therapeutics by 7.9% in the second quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 1,200 shares during the period. Metropolitan Life Insurance Co. NY grew its position in Aratana Therapeutics by 17.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock valued at $136,000 after acquiring an additional 3,883 shares during the period. Finally, Voya Investment Management LLC grew its position in Aratana Therapeutics by 22.7% in the second quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 3,610 shares during the period. Hedge funds and other institutional investors own 73.07% of the company’s stock.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related stocks with our FREE daily email newsletter.